CALC

CalciMedica, Inc. (NASDAQ:CALC) is a clinical-stage biotechnology company founded to develop innovative therapies for life-threatening inflammatory diseases. Based in La Jolla, California, the company went public in June 2023 and focuses on a proprietary technology platform that targets calcium release-activated calcium (CRAC) channels to modulate immune responses and protect against tissue damage in severe inflammatory conditions. CalciMedica represents an emerging player in the specialized field of calcium channel inhibition for therapeutic applications.